Parallel Advisors LLC Has $786,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Parallel Advisors LLC lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 16.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 1,104 shares of the biopharmaceutical company’s stock after selling 220 shares during the period. Parallel Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $786,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Principal Financial Group Inc. raised its holdings in Regeneron Pharmaceuticals by 1.7% in the 3rd quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock valued at $181,961,000 after acquiring an additional 2,828 shares during the period. Intact Investment Management Inc. bought a new position in Regeneron Pharmaceuticals in the 4th quarter valued at about $356,000. Golden State Equity Partners raised its holdings in Regeneron Pharmaceuticals by 1,479.1% in the 4th quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company’s stock valued at $967,000 after acquiring an additional 1,272 shares during the period. Fagan Associates Inc. raised its holdings in Regeneron Pharmaceuticals by 42.2% in the 4th quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company’s stock valued at $9,205,000 after acquiring an additional 3,832 shares during the period. Finally, ABC Arbitrage SA bought a new position in Regeneron Pharmaceuticals in the 4th quarter valued at about $1,510,000. 83.31% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have weighed in on REGN shares. Sanford C. Bernstein lowered their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. BMO Capital Markets decreased their target price on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 4th. Truist Financial decreased their target price on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. Citigroup decreased their target price on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Finally, TD Cowen decreased their target price on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $672.36 on Thursday. The company has a market cap of $73.51 billion, a price-to-earnings ratio of 17.56, a PEG ratio of 2.34 and a beta of 0.27. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The firm has a 50 day simple moving average of $691.62 and a 200 day simple moving average of $822.93. Regeneron Pharmaceuticals, Inc. has a one year low of $642.00 and a one year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter last year, the firm earned $11.86 earnings per share. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.52%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is currently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.